|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Transcription
|
 |
|
Title:
|
 |
The crystal structure of human steroidogenic factor-1
|
|
Structure:
|
 |
Steroidogenic factor 1. Chain: a, b. Synonym: stf-1, sf-1, adrenal 4 binding protein, steroid hormone receptor ad4bp, fushi tarazu factor homolog 1. Engineered: yes. Mutation: yes. Nuclear receptor coactivator 2. Chain: p, q. Fragment: residues 741-752.
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli. Expression_system_taxid: 562. Synthetic: yes. Other_details: this sequence occurs naturally in humans
|
|
Biol. unit:
|
 |
Dimer (from
)
|
|
Resolution:
|
 |
|
2.10Å
|
R-factor:
|
0.218
|
R-free:
|
0.265
|
|
|
Authors:
|
 |
W.Wang,C.Zhang,A.Marimuthu,H.I.Krupka,M.Tabrizizad,R.Shelloe,U.Mehra, K.Eng,H.Nguyen,C.Settachatgul,B.Powell,M.V.Milburn,B.L.West
|
Key ref:
|
 |
W.Wang
et al.
(2005).
The crystal structures of human steroidogenic factor-1 and liver receptor homologue-1.
Proc Natl Acad Sci U S A,
102,
7505-7510.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
14-Apr-05
|
Release date:
|
24-May-05
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
Q13285
(STF1_HUMAN) -
Steroidogenic factor 1 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
461 a.a.
233 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
Chains A, B, P, Q:
E.C.?
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Proc Natl Acad Sci U S A
102:7505-7510
(2005)
|
|
PubMed id:
|
|
|
|
|
| |
|
The crystal structures of human steroidogenic factor-1 and liver receptor homologue-1.
|
|
W.Wang,
C.Zhang,
A.Marimuthu,
H.I.Krupka,
M.Tabrizizad,
R.Shelloe,
U.Mehra,
K.Eng,
H.Nguyen,
C.Settachatgul,
B.Powell,
M.V.Milburn,
B.L.West.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Steroidogenic factor-1 (SF-1) and liver receptor homologue-1 (LRH-1) belong to
the fushi tarazu factor 1 subfamily of nuclear receptors. SF-1 is an essential
factor for sex determination during development and regulates adrenal and
gonadal steroidogenesis in the adult, whereas LRH-1 is a critical factor for
development of endodermal tissues and regulates cholesterol and bile acid
homeostasis. Regulatory ligands are unknown for SF-1 and LRH-1. A reported mouse
LRH-1 structure revealed an empty pocket in a region commonly occupied by
ligands in the structures of other nuclear receptors, and pocket-filling
mutations did not alter the constitutive activity observed. Here we report the
crystal structures of the putative ligand-binding domains of human SF-1 at 2.1-A
resolution and human LRH-1 at 2.5-A resolution. Both structures bind a
coactivator-derived peptide at the canonical activation-function surface, thus
adopting the transcriptionally activating conformation. In human LRH-1,
coactivator peptide binding also occurs to a second site. We discovered in both
structures a phospholipid molecule bound in a pocket of the putative
ligand-binding domain. MS analysis of the protein samples used for
crystallization indicated that the two proteins associate with a range of
phospholipids. Mutations of the pocket-lining residues reduced the
transcriptional activities of SF-1 and LRH-1 in mammalian cell transfection
assays without affecting their expression levels. These results suggest that
human SF-1 and LRH-1 may be ligand-binding receptors, although it remains to be
seen if phospholipids or possibly other molecules regulate SF-1 or LRH-1 under
physiological conditions.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Fig. 1. The hSF-1 and hLRH-1 LBD structures complexed with
phospholipid and coactivator peptide. (A and B) The hSF-1 LBD
(A) and the hLRH-1 LBD (B) (gray ribbon models) with
phospholipid ligands (spherical model colored by atom type), and
NCOA2 coactivator peptide (blue ribbon model). Note that two
NCOA2 peptides bind to each LRH-1 molecule, one at the canonical
activation function surface and the other at a site formed by
H2, H3, and the -sheet. (C) Residues of
the hSF-1 ligand-binding pocket (stick models colored yellow and
by atom type), showing salt bridge and hydrogen bonds (dotted
lines) to the PE (stick models colored white and by atom type).
The blue mesh indicates an unbiased 2F[o] - F[c] map covering
the ligand. H2 and H3 are truncated to show the pocket features.
(D) Residues of the hLRH-1 ligand-binding pocket depicted as in
C showing interactions with the
phosphatidylglycerol-phosphoglycerol.
|
 |
Figure 2.
Fig. 2. Comparison of hSF-1 and hLRH-1 structures with
mLRH-1. (A and B) A phosphate group in hSF-1 (A) and hLRH-1 (B)
interacts with the Lys and Tyr of the KYG triad. (C) E440 in the
APO mLRH-1 mimics the phosphate group interactions. Only the
residues of the phosphate-binding triad (sticks colored yellow
and by atom type) and the polar portions of the phospholipids
(sticks colored by atom type) are shown. (D) Alignment of
representative NR5A sequences. The two sequence segments that
contain the KYG motif (helix H6-H7 and H11) are shown. A more
complete alignment appears in Fig. 8.
|
 |
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
P.M.Musille,
M.C.Pathak,
J.L.Lauer,
W.H.Hudson,
P.R.Griffin,
and
E.A.Ortlund
(2012).
Antidiabetic phospholipid-nuclear receptor complex reveals the mechanism for phospholipid-driven gene regulation.
|
| |
Nat Struct Mol Biol,
19,
532.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
P.T.Thiruchelvam,
C.F.Lai,
H.Hua,
R.S.Thomas,
A.Hurtado,
W.Hudson,
A.R.Bayly,
F.J.Kyle,
M.Periyasamy,
A.Photiou,
A.C.Spivey,
E.A.Ortlund,
R.J.Whitby,
J.S.Carroll,
R.C.Coombes,
L.Buluwela,
and
S.Ali
(2011).
The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cells.
|
| |
Breast Cancer Res Treat,
127,
385-396.
|
 |
|
|
|
|
 |
G.Zollner,
M.Wagner,
and
M.Trauner
(2010).
Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity.
|
| |
Pharmacol Ther,
126,
228-243.
|
 |
|
|
|
|
 |
M.Cellanetti,
V.Gunda,
L.Wang,
A.Macchiarulo,
and
R.Pellicciari
(2010).
Insights into the binding mode and mechanism of action of some atypical retinoids as ligands of the small heterodimer partner (SHP).
|
| |
J Comput Aided Mol Des,
24,
943-956.
|
 |
|
|
|
|
 |
M.Ohno,
J.Komakine,
E.Suzuki,
M.Nishizuka,
S.Osada,
and
M.Imagawa
(2010).
Repression of the promoter activity mediated by liver receptor homolog-1 through interaction with ku proteins.
|
| |
Biol Pharm Bull,
33,
784-791.
|
 |
|
|
|
|
 |
S.Mukherjee,
and
S.Mani
(2010).
Orphan nuclear receptors as targets for drug development.
|
| |
Pharm Res,
27,
1439-1468.
|
 |
|
|
|
|
 |
C.Yokoyama,
T.Komatsu,
H.Ogawa,
K.Morohashi,
M.Azuma,
and
T.Tachibana
(2009).
Generation of rat monoclonal antibodies specific for Ad4BP/SF-1.
|
| |
Hybridoma (Larchmt),
28,
113-119.
|
 |
|
|
|
|
 |
G.B.Rha,
G.Wu,
S.E.Shoelson,
and
Y.I.Chi
(2009).
Multiple binding modes between HNF4alpha and the LXXLL motifs of PGC-1alpha lead to full activation.
|
| |
J Biol Chem,
284,
35165-35176.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
G.Zollner,
and
M.Trauner
(2009).
Nuclear receptors as therapeutic targets in cholestatic liver diseases.
|
| |
Br J Pharmacol,
156,
7.
|
 |
|
|
|
|
 |
M.B.Sewer,
and
S.Jagarlapudi
(2009).
Complex assembly on the human CYP17 promoter.
|
| |
Mol Cell Endocrinol,
300,
109-114.
|
 |
|
|
|
|
 |
M.Noti,
D.Sidler,
and
T.Brunner
(2009).
Extra-adrenal glucocorticoid synthesis in the intestinal epithelium: more than a drop in the ocean?
|
| |
Semin Immunopathol,
31,
237-248.
|
 |
|
|
|
|
 |
E.P.Sablin,
A.Woods,
I.N.Krylova,
P.Hwang,
H.A.Ingraham,
and
R.J.Fletterick
(2008).
The structure of corepressor Dax-1 bound to its target nuclear receptor LRH-1.
|
| |
Proc Natl Acad Sci U S A,
105,
18390-18395.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
E.R.Prossnitz,
J.B.Arterburn,
H.O.Smith,
T.I.Oprea,
L.A.Sklar,
and
H.J.Hathaway
(2008).
Estrogen signaling through the transmembrane G protein-coupled receptor GPR30.
|
| |
Annu Rev Physiol,
70,
165-190.
|
 |
|
|
|
|
 |
J.Roth,
F.Madoux,
P.Hodder,
and
W.R.Roush
(2008).
Synthesis of small molecule inhibitors of the orphan nuclear receptor steroidogenic factor-1 (NR5A1) based on isoquinolinone scaffolds.
|
| |
Bioorg Med Chem Lett,
18,
2628-2632.
|
 |
|
|
|
|
 |
L.A.Campbell,
E.J.Faivre,
M.D.Show,
J.G.Ingraham,
J.Flinders,
J.D.Gross,
and
H.A.Ingraham
(2008).
Decreased recognition of SUMO-sensitive target genes following modification of SF-1 (NR5A1).
|
| |
Mol Cell Biol,
28,
7476-7486.
|
 |
|
|
|
|
 |
L.Lin,
and
J.C.Achermann
(2008).
Steroidogenic factor-1 (SF-1, Ad4BP, NR5A1) and disorders of testis development.
|
| |
Sex Dev,
2,
200-209.
|
 |
|
|
|
|
 |
T.Zhang,
J.H.Zhou,
L.W.Shi,
R.X.Zhu,
and
M.B.Chen
(2008).
Molecular dynamics simulation study for LRH-1: interaction with fragments of SHP and function of phospholipid ligand.
|
| |
Proteins,
70,
1527-1539.
|
 |
|
|
|
|
 |
A.Coste,
L.Dubuquoy,
R.Barnouin,
J.S.Annicotte,
B.Magnier,
M.Notti,
N.Corazza,
M.C.Antal,
D.Metzger,
P.Desreumaux,
T.Brunner,
J.Auwerx,
and
K.Schoonjans
(2007).
LRH-1-mediated glucocorticoid synthesis in enterocytes protects against inflammatory bowel disease.
|
| |
Proc Natl Acad Sci U S A,
104,
13098-13103.
|
 |
|
|
|
|
 |
C.Mataki,
B.C.Magnier,
S.M.Houten,
J.S.Annicotte,
C.Argmann,
C.Thomas,
H.Overmars,
W.Kulik,
D.Metzger,
J.Auwerx,
and
K.Schoonjans
(2007).
Compromised intestinal lipid absorption in mice with a liver-specific deficiency of liver receptor homolog 1.
|
| |
Mol Cell Biol,
27,
8330-8339.
|
 |
|
|
|
|
 |
D.Li,
A.N.Urs,
J.Allegood,
A.Leon,
A.H.Merrill,
and
M.B.Sewer
(2007).
Cyclic AMP-stimulated interaction between steroidogenic factor 1 and diacylglycerol kinase theta facilitates induction of CYP17.
|
| |
Mol Cell Biol,
27,
6669-6685.
|
 |
|
|
|
|
 |
H.C.Lan,
H.J.Li,
G.Lin,
P.Y.Lai,
and
B.C.Chung
(2007).
Cyclic AMP stimulates SF-1-dependent CYP11A1 expression through homeodomain-interacting protein kinase 3-mediated Jun N-terminal kinase and c-Jun phosphorylation.
|
| |
Mol Cell Biol,
27,
2027-2036.
|
 |
|
|
|
|
 |
L.Lin,
P.Philibert,
B.Ferraz-de-Souza,
D.Kelberman,
T.Homfray,
A.Albanese,
V.Molini,
N.J.Sebire,
S.Einaudi,
G.S.Conway,
I.A.Hughes,
J.L.Jameson,
C.Sultan,
M.T.Dattani,
and
J.C.Achermann
(2007).
Heterozygous missense mutations in steroidogenic factor 1 (SF1/Ad4BP, NR5A1) are associated with 46,XY disorders of sex development with normal adrenal function.
|
| |
J Clin Endocrinol Metab,
92,
991-999.
|
 |
|
|
|
|
 |
P.Philibert,
D.Zenaty,
L.Lin,
S.Soskin,
F.Audran,
J.Léger,
J.C.Achermann,
and
C.Sultan
(2007).
Mutational analysis of steroidogenic factor 1 (NR5a1) in 24 boys with bilateral anorchia: a French collaborative study.
|
| |
Hum Reprod,
22,
3255-3261.
|
 |
|
|
|
|
 |
W.Y.Chen,
J.H.Weng,
C.C.Huang,
and
B.C.Chung
(2007).
Histone deacetylase inhibitors reduce steroidogenesis through SCF-mediated ubiquitination and degradation of steroidogenic factor 1 (NR5A1).
|
| |
Mol Cell Biol,
27,
7284-7290.
|
 |
|
|
|
|
 |
M.Mueller,
I.Cima,
M.Noti,
A.Fuhrer,
S.Jakob,
L.Dubuquoy,
K.Schoonjans,
and
T.Brunner
(2006).
The nuclear receptor LRH-1 critically regulates extra-adrenal glucocorticoid synthesis in the intestine.
|
| |
J Exp Med,
203,
2057-2062.
|
 |
|
|
|
|
 |
N.Venteclef,
J.C.Smith,
B.Goodwin,
and
P.Delerive
(2006).
Liver receptor homolog 1 is a negative regulator of the hepatic acute-phase response.
|
| |
Mol Cell Biol,
26,
6799-6807.
|
 |
|
|
|
|
 |
N.Walther,
M.Jansen,
W.Akbary,
and
R.Ivell
(2006).
Differentiation-specific action of orphan nuclear receptor NR5A1 (SF-1): transcriptional regulation in luteinizing bovine theca cells.
|
| |
Reprod Biol Endocrinol,
4,
64.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |
|